SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023) [Yahoo! Finance]
SAB Biotherapeutics, Inc. (SABS)
Company Research
Source: Yahoo! Finance
All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is forecast to grow 9.9% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 9.5% from a week ago. What about risks? Every company has them, and we've spotted 7 warning signs for SAB Biotherapeutics (of which 4 don't sit too well with us!) you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or you
Show less
Read more
Impact Snapshot
Event Time:
SABS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SABS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SABS alerts
High impacting SAB Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SABS
News
- SAB Biotherapeutics Leads The Pack Of 3 US Penny Stocks To Consider [Yahoo! Finance]Yahoo! Finance
- SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.MarketBeat
- SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company UpdateGlobeNewswire
- SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation ConferenceGlobeNewswire
- SAB Biotherapeutics, Inc. (NASDAQ: SABS) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $11.00 price target on the stock.MarketBeat
SABS
Earnings
- 11/6/24 - Miss
SABS
Sec Filings
- 11/6/24 - Form 10-Q
- 11/5/24 - Form 4
- SABS's page on the SEC website